Abstract:Simple Summary The formats of bispecific antibody have been investigated for many years to enhance the stability of the structure and anti-tumor efficacy. One of the formats combining two Fabs at their C termini provides unmodified variable region and comparable activity to other fragment-based bispecific antibodies that are usually combined in a head-to-tail manner. However, the current strategy to produce the BiFab molecule is limited to a semisynthetic method that introduces unnatural amino acid to antibodies' sequences during production. To improve the application of BiFab format in investigational biodrugs, we have applied sortase A-mediated "bio-click" chemistry to generate BiFab, for facile assembly of Fab molecules that have been expressed and stored as BiFab module candidates. The BiFabs made by our method stimulate T cell proliferation and activation with favorable in vitro and in vivo anti-tumor activit. Our results indicate that BiFab made by sortase A-mediated click chemistry could be used to efficiently generate various BiFabs with high potency, which further supports personalized tumor immunotherapy in the future. Bispecific antibodies (BsAbs) for T cell engagement have shown great promise in cancer immunotherapy, and their clinical applications have been proven in treating hematological malignance. Bispecific antibody binding fragment (BiFab) represents a promising platform for generating non-Fc bispecific antibodies. However, the generation of BiFab is still challenging, especially by means of chemical conjugation. More conjugation strategies, e.g., enzymatic conjugation and modular BiFab preparation, are needed to improve the robustness and flexibility of BiFab preparation. We successfully used chemo-enzymatic conjugation approach to generate bispecific antibody (i.e., BiFab) with Fabs from full-length antibodies. Paired click handles (e.g., N-3 and DBCO) was introduced to the C-terminal LPETG tag of Fabs via sortase A mediated transpeptidation, followed by site-specific conjugation between two click handle-modified Fabs for BiFab generation. Both BiFab(CD20/CD3) (EC50 = 0.26 ng/mL) and BiFab(Her2/CD3) exhibited superior efficacy in mediating T cells, from either PBMC or ATC, to kill target tumor cell lines while spared antigen-negative tumor cells in vitro. The BiFab(CD20/CD3) also efficiently inhibited CD20-positive tumor growth in mouse xenograft model. We have established a facile sortase A-mediated click handle installation to generate homogeneous and functional BiFabs. The exemplary BiFabs against different targets showed superior efficacy in redirecting and activating T cells to specifically kill target tumor cells, demonstrating the robustness of sortase A-mediated "bio-click" chemistry in generating various potent BiFabs. This approach also holds promise for further efficient construction of a Fab derivative library for personalized tumor immunotherapy in the future.

Recombinant Human CD137L for Cancer Immunotherapy: Effects of Different Fusions and Linkers on Its Activity

Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.

Soluble expression of recombinant human CD137 ligand in Escherichia coli by co-expression of chaperones

A Novel Recombinant Fusion Protein with Soluble PD-1 and TIM-3 Domains Effectively Binds to Cancer Cells

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy

[Construction, Expression and Purification of a Mammalian Secretory Recombinant Fusion Protein Rpc].

Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers

CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy

Molecular Construction and Characterization of a Novel Exotoxin Fusion Protein That Selectively Blocks the B7:CD28 Costimulatory Signal System

A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors

A Novel Bifunctional Fusion Protein Comprising of TGF-βRII trap and IL15/IL-15Rα as an Immunotherapeutic against Cancer

Optimization of culture conditions for stable expression of recombinant fc-fused human extracellular CD99 in HEK293T cells

Fusion Protein of CDR Mimetic Peptide with Fc Inhibit TNF-α Induced Cytotoxicity

Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application

Abstract 2717: Bifunctional fusion protein PDL1sFv/MICAe for cancer immunotherapy

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Abstract 5623: CD137 humanized mice for preclinical efficacy evaluation of therapeutic antibodies

Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents

Display of CCL21 on cancer cell membrane through genetic modification using a pH low insertion peptide

Immunotherapy with agonistic anti-CD137: two sides of a coin.